TerraBioGen Technologies closes $576K private placement

pcNewsWireTerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, has closed a private placement of 192,000 units at $3.00 per unit for proceeds of $576,000.

Proceeds will be used to further the company’s internal research and development, continue collaboration with its university partners, and enhance commercialization efforts through it next generation formulations and cooperative field trials.

News Release

TerraBioGen Closes Private Placement

Vancouver, Canada, June 29, 2017

TerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, announces that it has closed a private placement.

The private placement is for 192,000 units at $3.00 per unit for proceeds of $576,000. Each unit consists of one common share and one warrant exercisable at $5.00 per common share for 5 years.

These funds will be used to further the company’s internal research and development, continue collaboration with its university partners, and enhance commercialization efforts through it next generation formulations and cooperative field trials.

About TerraBioGen

TerraBioGen Technologies Inc. is a developer of innovative, proprietary, high-value, environmentally sustainable bioproducts and biostimulants that improve crop health and yields, and increase abiotic and biotic stress tolerance in agricultural and horticultural crops. The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Further, the Company is taking steps to secure intellectual property rights to these bioproducts and to formulate them in order to fully commercialize their potential.

For more information, please contact:

Blair Heffelfinger
President & CEO
TerraBioGen Technologies Inc.
bheffelfinger@terrabiogen.com
(604) 444-1023 ext 316
(604) 444-1043 fax

Tanya Sedlacek
Controller & Corporate Secretary
TerraBioGen Technologies Inc.
tsedlacek@terrabiogen.com
(604) 444-1023 ext 306
(604) 444-1043 fax